Literature DB >> 19778764

Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.

Pamela A Moise1, Donald North, Judith N Steenbergen, George Sakoulas.   

Abstract

The decrease in vancomycin treatment efficacy that is accompanying increases in vancomycin minimum inhibitory concentration (MIC) within the susceptible range (so-called MIC creep) has led to the suggestion that vancomycin is losing its potency in treating serious Staphylococcus aureus infections. Understanding the clinical importance of the microbiological effects of glycopeptides on bacterial lipopeptides and lipoglycopeptides will be crucial in treating serious meticillin-resistant S aureus infections. We review the observed effects of reduced glycopeptide susceptibility on the activities of daptomycin in S aureus in vitro and in vivo. Factors associated with loss of susceptibility and ways to reduce the risk of resistance to daptomycin are reviewed, including the importance of prompt mechanical reduction of bacterial inoculum through surgery or through potent or combination antibiotic therapy, as well as optimisation of daptomycin pharmacodynamic exposure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19778764     DOI: 10.1016/S1473-3099(09)70200-2

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  38 in total

1.  Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  C Garrigós; O Murillo; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010.

Authors:  B Edwards; K Milne; T Lawes; I Cook; A Robb; I M Gould
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

3.  Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.

Authors:  Chen-Hsiang Lee; Ming-Chung Wang; I-Wen Huang; Feng-Jui Chen; Tsai-Ling Lauderdale
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

4.  Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans.

Authors:  Clayton Harro; Robert Betts; Walter Orenstein; Eun-Jeong Kwak; Howard E Greenberg; Matthew T Onorato; Jon Hartzel; Joy Lipka; Mark J DiNubile; Nicholas Kartsonis
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

Review 5.  Interplay between Candida albicans and the antimicrobial peptide armory.

Authors:  Marc Swidergall; Joachim F Ernst
Journal:  Eukaryot Cell       Date:  2014-06-20

6.  Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus.

Authors:  Mélanie Roch; Perrine Clair; Adriana Renzoni; Marie-Elisabeth Reverdy; Olivier Dauwalder; Michèle Bes; Annie Martra; Anne-Marie Freydière; Frédéric Laurent; Philippe Reix; Oana Dumitrescu; François Vandenesch
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

7.  Glycopeptide and daptomycin resistance in community-associated MRSA in the UK.

Authors:  A Kirby; C Edwards; C M Broughton; N J Williams
Journal:  Infection       Date:  2011-04-01       Impact factor: 3.553

Review 8.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

9.  Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.

Authors:  Pamela A Moise; Maria Amodio-Groton; Mohamad Rashid; Kenneth C Lamp; Holly L Hoffman-Roberts; George Sakoulas; Min J Yoon; Suzanne Schweitzer; Anjay Rastogi
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

10.  Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection.

Authors:  Wei Gao; Kyra Chua; John K Davies; Hayley J Newton; Torsten Seemann; Paul F Harrison; Natasha E Holmes; Hyun-Woo Rhee; Jong-In Hong; Elizabeth L Hartland; Timothy P Stinear; Benjamin P Howden
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.